[Proteins modified in the nonenzymatically glycosylation reaction (AGE-proteins)--new markers for diabetes?].
Paper present a recent review on the formation and clinical significance of advanced glycosylation end products, produced in nonenzymatically glycosylation, called Maillard reaction. The special attention was paid to AGEs role in diabetic and aging processes. Instant of occurring of AGEs in circulation or increase of AGE receptor concentration are many years faster than clinical pathology of vessels, nervous or kidneys connect with diabetes or aging. May be in the future it will be possible to decrease the consequence of Maillard reaction by using pharmacology drugs.
Zdrojewicz
Z
Z
Katedra i Klinika Endokrynologii, Akademii Medycznej we Wrocławiu.
Januszewski
A
A
Kwiatkowska
D
D
D000375:Aging / Q000378:metabolism; D015415:Biomarkers / Q000032:analysis; D003920:Diabetes Mellitus / Q000175:diagnosis / Q000378:metabolism*; D017127:Glycation End Products, Advanced / Q000032:analysis / Q000378:metabolism*; D006801:Humans; D015416:Maillard Reaction; D008565:Membrane Proteins / Q000378:metabolism
D015415:Biomarkers; D017127:Glycation End Products, Advanced; D008565:Membrane Proteins
Białka zmodyfikowane w reakcji nieenzymatycznej glikozylacji (AGE-proteiny)--nowe markery w cukrzycy?